Asia Beat: Enlightened Astellas in need of transcendental Medivation?
This article was originally published in Scrip
Executive Summary
The buzz surrounding Medivation's novel prostate cancer drug enzalutamide is creating inevitable speculation that global partner Astellas may launch an acquisition bid for the originator of one of its brightest mid-term prospects.